[
  {
    "ts": "2025-12-22T08:58:00+00:00",
    "headline": "Should You Forget Novo Nordisk and Buy This Magnificent High-Yield Drug Stock Instead?",
    "summary": "Novo Nordisk gained a head start in the GLP-1 race but then fell behind; Pfizer is working hard to catch up to the new leader.",
    "url": "https://www.fool.com/investing/2025/12/22/forget-novo-nordisk-buy-high-yield-drug-stock/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "2c160554-0225-3523-ac6e-41ac27dc9837",
      "content": {
        "id": "2c160554-0225-3523-ac6e-41ac27dc9837",
        "contentType": "STORY",
        "title": "Should You Forget Novo Nordisk and Buy This Magnificent High-Yield Drug Stock Instead?",
        "description": "",
        "summary": "Novo Nordisk gained a head start in the GLP-1 race but then fell behind; Pfizer is working hard to catch up to the new leader.",
        "pubDate": "2025-12-22T08:58:00Z",
        "displayTime": "2025-12-22T08:58:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/34be29d992e20b626208f7610cd6ad29",
          "originalWidth": 1200,
          "originalHeight": 801,
          "caption": "A medical professional filling a needle from a bottle of medicine.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4FLKocTE8Dy4an3gq.W46A--~B/aD04MDE7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/34be29d992e20b626208f7610cd6ad29.cf.webp",
              "width": 1200,
              "height": 801,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OjZI_UgWLI8P7SE8GyR7Cw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/34be29d992e20b626208f7610cd6ad29.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/12/22/forget-novo-nordisk-buy-high-yield-drug-stock/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/forget-novo-nordisk-buy-magnificent-085800517.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-22T09:59:07+00:00",
    "headline": "Abivax soars on report of Eli Lilly meeting French officials over possible deal",
    "summary": "Investing.com -- Abivax shares jumped after fresh media reports revived speculation that U.S. drugmaker Eli Lilly is exploring a takeover of the French biotech company.",
    "url": "https://finance.yahoo.com/news/abivax-soars-report-eli-lilly-095907134.html",
    "source": "Investing.com",
    "provider": "yfinance",
    "raw": {
      "id": "0b3c9723-f11f-35e7-b056-b8543a20195a",
      "content": {
        "id": "0b3c9723-f11f-35e7-b056-b8543a20195a",
        "contentType": "STORY",
        "title": "Abivax soars on report of Eli Lilly meeting French officials over possible deal",
        "description": "",
        "summary": "Investing.com -- Abivax shares jumped after fresh media reports revived speculation that U.S. drugmaker Eli Lilly is exploring a takeover of the French biotech company.",
        "pubDate": "2025-12-22T09:59:07Z",
        "displayTime": "2025-12-22T09:59:07Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Investing.com",
          "url": "https://www.investing.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/abivax-soars-report-eli-lilly-095907134.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abivax-soars-report-eli-lilly-095907134.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AAVXF"
            },
            {
              "symbol": "ABVX"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "ADVM"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-22T11:50:10+00:00",
    "headline": "Here is Why H.C. Wainwright Sees Immense Upside for Viking Therapeutics (VKTX)",
    "summary": "Viking Therapeutics (NASDAQ:VKTX) is one of the most promising mid-cap healthcare stocks under $50. On December 18, H.C. Wainwright analyst Joseph Pantginis reaffirmed his Buy rating on Viking Therapeutics (NASDAQ:VKTX). The analyst has forecasted a huge upside potential of almost 190% from the prevailing range, with a price target of $102 a share. Pantginis maintains […]",
    "url": "https://finance.yahoo.com/news/why-h-c-wainwright-sees-115010878.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "2c2bc334-972a-3bd4-b3f5-66a77de011fd",
      "content": {
        "id": "2c2bc334-972a-3bd4-b3f5-66a77de011fd",
        "contentType": "STORY",
        "title": "Here is Why H.C. Wainwright Sees Immense Upside for Viking Therapeutics (VKTX)",
        "description": "",
        "summary": "Viking Therapeutics (NASDAQ:VKTX) is one of the most promising mid-cap healthcare stocks under $50. On December 18, H.C. Wainwright analyst Joseph Pantginis reaffirmed his Buy rating on Viking Therapeutics (NASDAQ:VKTX). The analyst has forecasted a huge upside potential of almost 190% from the prevailing range, with a price target of $102 a share. Pantginis maintains […]",
        "pubDate": "2025-12-22T11:50:10Z",
        "displayTime": "2025-12-22T11:50:10Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/c7cbbfaa5b33f51cedabc8bab9f6be5c",
          "originalWidth": 1000,
          "originalHeight": 668,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_ZfoJ4THRdWEUJIk6yi7sg--~B/aD02Njg7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/c7cbbfaa5b33f51cedabc8bab9f6be5c.cf.webp",
              "width": 1000,
              "height": 668,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3VSaBedNr1qF1wBLp8RjEA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/c7cbbfaa5b33f51cedabc8bab9f6be5c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-h-c-wainwright-sees-115010878.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-h-c-wainwright-sees-115010878.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VKTX"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-22T04:37:24+00:00",
    "headline": "2 Profitable Stocks with Exciting Potential and 1 Facing Challenges",
    "summary": "Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.",
    "url": "https://finance.yahoo.com/news/2-profitable-stocks-exciting-potential-043724219.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "f5de3703-479f-3323-8de8-e339f117c8f6",
      "content": {
        "id": "f5de3703-479f-3323-8de8-e339f117c8f6",
        "contentType": "STORY",
        "title": "2 Profitable Stocks with Exciting Potential and 1 Facing Challenges",
        "description": "",
        "summary": "Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.",
        "pubDate": "2025-12-22T04:37:24Z",
        "displayTime": "2025-12-22T04:37:24Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/43ca9a61a8734ba68ffae324770ff9e0",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "UNP Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/V4xbv_.Ir4Zn.ad7Q_QE.g--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/43ca9a61a8734ba68ffae324770ff9e0.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/UUEyrLCA7DVNbn9y2xfQ8A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/43ca9a61a8734ba68ffae324770ff9e0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/2-profitable-stocks-exciting-potential-043724219.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/2-profitable-stocks-exciting-potential-043724219.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "ARES"
            },
            {
              "symbol": "UNP"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-22T13:30:00+00:00",
    "headline": "CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies",
    "summary": "-Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy data suggest significant clinical improvement in patients dosed at the 100 million cell dose, with the first systemic lupus erythematosus (SLE) patient achieving Definitions of Remission in SLE (DORIS) remission through Month 6- -An additional Phase 1 basket trial has been initiated for zugo-cel in refractory primary immune thrombocytopenic purpura (ITP) and warm autoimmun",
    "url": "https://finance.yahoo.com/news/crispr-therapeutics-provides-broad-zugocaptagene-133000753.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "e4655848-37df-34c5-8e9e-c819e2bb7596",
      "content": {
        "id": "e4655848-37df-34c5-8e9e-c819e2bb7596",
        "contentType": "STORY",
        "title": "CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies",
        "description": "",
        "summary": "-Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy data suggest significant clinical improvement in patients dosed at the 100 million cell dose, with the first systemic lupus erythematosus (SLE) patient achieving Definitions of Remission in SLE (DORIS) remission through Month 6- -An additional Phase 1 basket trial has been initiated for zugo-cel in refractory primary immune thrombocytopenic purpura (ITP) and warm autoimmun",
        "pubDate": "2025-12-22T13:30:00Z",
        "displayTime": "2025-12-22T13:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/1aff8de1b43a5c2c983997aa98d58aad",
          "originalWidth": 1800,
          "originalHeight": 1957,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/mnPsJEczvucHirpNfZ3Hpg--~B/aD0xOTU3O3c9MTgwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/1aff8de1b43a5c2c983997aa98d58aad.cf.webp",
              "width": 1800,
              "height": 1957,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8jC0wMX28ixyv6Mj1oYr_A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/1aff8de1b43a5c2c983997aa98d58aad.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/crispr-therapeutics-provides-broad-zugocaptagene-133000753.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/crispr-therapeutics-provides-broad-zugocaptagene-133000753.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CRSP"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]